Bone Marrow Transplant
|Recruiting||Adult Acute Myeloid Leukemia (AML)
Childhood Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Secondary Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving azacitidine together with gemtuzumab ozogamicin may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving azacitidine together with gemtuzumab ozogamicin works in treating patients relapsed myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia who have undergone stem cell transplant.
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
- MDS, CMML or AML patients (as diagnosed by WHO criteria) with evidence of relapse or progression at >= day 28 and < day 100 post-transplant
- Recurrent or increased cytogenetic abnormalities by standard karyotype or FISH (the cytogenetic abnormalities must have been previously documented at some time point between diagnosis and date of stem cell transplant)
- Morphologic evidence of recurrence or increased abnormal myeloblasts in peripheral blood or marrow
- Flow Cytometric evidence of disease as determined by recurrent or increased abnormal myeloblasts in peripheral blood or marrow
- Extramedullary relapse (local radiotherapy will be allowed)
- MDS, CMML, or AML patients with persistent stable disease or persistent disease with regression at >= day 28 and < day 100 post-transplant
- Persistence of cytogenetic abnormalities by standard karyotype or FISH
- Persistent morphologic evidence of abnormal myeloblasts (in patients with CMML the monoblastoid population is included) in peripheral blood or marrow
- Persistent flow cytometric evidence of abnormal myeloblasts (in patients with CMML the monoblastoid population is included) in peripheral blood or marrow
- Extramedullary persistence or regression
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.